Harpoon Therapeutics Inc HARP:NASDAQ

Last Price$2.47Cboe Real-Time Last Sale as of 2:54PM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.16(6.08%)
Bid (Size)$2.46 (223)
Ask (Size)$2.48 (100)
Day Low / High$2.36 - 2.79
Volume194.1 K
 

View Biotechnology IndustryPeer Comparison as of 05/20/2022

 

Harpoon Therapeutics Inc ( NASDAQ )

Price: $2.47
Change: -0.16 (6.08%)
Volume: 194.1 K
2:54PM ET 5/20/2022
 
 

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $1.79
Change: -0.04 (2.19%)
Volume: 42.9 K
1:22PM ET 5/20/2022
 
 

Epizyme Inc ( NASDAQ )

Price: $0.50
Change: -0.03 (5.45%)
Volume: 954.6 K
3:27PM ET 5/20/2022
 
 

Equillium Inc ( NASDAQ )

Price: $2.47
Change: -0.06 (2.37%)
Volume: 18.3 K
11:59AM ET 5/20/2022
 
 

Magenta Therapeutics Inc ( NASDAQ )

Price: $1.20
Change: -0.26 (17.81%)
Volume: 451.6 K
3:02PM ET 5/20/2022
 

Read more news Recent News

Harpoon Therapeutics Shares Soar After Wedbush Upgrade
1:23PM ET 5/16/2022 MT Newswires

Harpoon Therapeutics (HARP) shares soared Monday afternoon after Wedbush upgraded the company's stock to outperform from neutral while raising its price...

Wedbush Upgrades Harpoon Therapeutics to Outperform From Neutral on Valuation, Lifts Price Target to $7 From $5
6:35AM ET 5/16/2022 MT Newswires

Harpoon Therapeutics (HARP) has an average rating of buy and price targets ranging from $5 to $18, according to analysts polled by Capital IQ. (MT...

Piper Sandler Adjusts Price Target on Harpoon Therapeutics to $14 From $15, Reiterates Overweight Rating
5:45AM ET 5/16/2022 MT Newswires

Harpoon Therapeutics (HARP) has an average rating of buy and price targets ranging from $5 to $18, according to analysts polled by Capital IQ. (MT...

-- Earnings Flash (HARP) HARPOON THERAPEUTICS Reports Q1 Loss $-0.62
4:23PM ET 5/12/2022 MT Newswires

...

Company Profile

Business DescriptionHarpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. View company web site for more details
Address131 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.650.443.7400
Number of Employees45
Recent SEC Filing05/12/20228-K
President, Chief Executive Officer & DirectorJulia Marie Eastland
Chief Financial Officer & SecretaryGeorgia L. Erbez
Chief Medical OfficerNatalie R. Sacks
Chief Scientific OfficerHolger Wesche

Company Highlights

Price Open$2.69
Previous Close$2.63
52 Week Range$1.73 - 22.74
Market Capitalization$81.7 M
Shares Outstanding33.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.53
Beta vs. S&P 500N/A
Revenue$4.8 M
Net Profit Margin-493.45%
Return on Equity-142.19%

Analyst Ratings as of 05/13/2022

Buy
9
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset